New RNA Therapy Targets KRAS in Cancer Models

Two complementary research led by researchers from the Yong Lavatory Lin College of Drugs, Nationwide College of Singapore (NUS Drugs), have demonstrated a brand new RNA-based therapeutic technique that successfully targets probably the most difficult-to-treat most cancers genes, Kirsten rat sarcoma viral oncogene homolog (KRAS), whereas stimulating the physique’s immune response to struggle tumours. The analysis was carried out in cell samples and laboratory fashions, with collaborators from the NUS Institute for Well being Innovation and Expertise (iHealthtech), Nanyang Technological College (NTU), Company for Science, Expertise and Analysis (A*STAR), and worldwide companions.

KRAS is a gene that acts like a molecular swap controlling how cells develop and divide. In wholesome cells, this swap activates and off as wanted. Nevertheless, in lots of cancers, together with pancreatic, lung, and colorectal cancers, the KRAS gene turns into mutated, locking the swap within the “on” place. This fixed activation drives uncontrolled cell progress and helps tumours evade regular immune defences. Mutations in KRAS are among the many most typical drivers of human cancers and are present in over 90% of pancreatic cancers[1]. Because the KRAS protein binds tightly to its signalling molecules and lacks easy-to-target binding websites, it has lengthy been thought-about “undruggable” — making it one of many hardest and most necessary targets in most cancers analysis.

The analysis crew developed a mix remedy utilizing antisense oligonucleotides (ASOs) to silence mutant KRAS genes and an immunomodulatory RNA (immRNA) that prompts the Retinoic acid-Inducible Gene I (RIG-I) immune pathway. The RIG-I pathway is akin to an alarm system in our cells, the place it detects viruses after which alerts our immune system to take care of the menace. Each the ASOs and immRNA molecules had been delivered safely utilizing purple blood cell-derived extracellular vesicles (RBCEVs), a pure, biocompatible provider for nucleic acid medication.

Within the first examine, revealed in Theranostics, the researchers confirmed that the mixed ASO–immRNA therapy killed KRAS-mutant most cancers cells—together with lung, colorectal, and pancreatic cancers—by concurrently blocking oncogenic KRAS exercise and triggering antiviral-like immune signalling. The twin therapy transformed “chilly” tumours that usually evade immune assault into “scorching” ones that the immune system can recognise and assault, lowering tumour burden and lengthening survival in laboratory research with out harming regular cells.

Constructing on these outcomes, the second examine, revealed within the Journal of Controlled Release on Science Direct, superior the remedy to the preclinical stage for pancreatic most cancers, primarily pancreatic ductal adenocarcinoma (PDAC), with peritoneal metastasis. PDAC is among the deadliest types of most cancers, with a 5-year survival price of 10%[2]. Nevertheless, the therapy markedly suppressed tumour progress, restricted stomach unfold, and extended survival in laboratory research. Importantly, security testing confirmed no observable toxicity in laboratory research, supporting its potential for future scientific analysis.

“KRAS mutations hijack most cancers cells and suppress immune responses, enabling metastasis,” mentioned Affiliate Professor Minh Le, Division of Pharmacology, and Institute for Digital Drugs (WisDM), NUS Drugs, “Our EV platform exactly targets mutants, sparing wholesome tissue, and synergises KRAS knockdown with RIG-I activation to unleash interferons, immunogenic cell dying, and T-cell reminiscence—halting tumour progress and lengthening survival with out toxicity.”

Affiliate Professor Glenn Bonney, Senior Guide, Division of Hepatobiliary & Pancreatic Surgical procedure, Division of Surgical procedure, Nationwide College Hospital (NUH), who contributed patient-derived organoids for the research, added, “This twin nucleic acid supply by way of biocompatible vesicles overcomes KRAS resistance boundaries, providing a secure, scalable path to deal with peritoneal metastasis—a serious unmet want in PDAC.”

Professor Dahai Luo, from NTU’s Lee Kong Chian College of Drugs and co-author of the papers, added, “By engineering EVs for focused supply, we’ve got turned pure cell messengers into precision weapons, with broad potential for different KRAS-addicted cancers like colorectal and lung.”

Adjunct Professor Jonathan Loh Yuin-Han, Deputy Govt Director (Analysis) on the Institute of Molecular and Cell Biology (IMCB), A*STAR and co-author of 1 publication, mentioned, “This revolutionary mixture of KRAS-targeting ASOs and RIG-I agonists delivered by way of extracellular vesicles reprograms the tumour microenvironment, charting a brand new path towards reworking KRAS-driven cancers and bringing us nearer to efficient, personalised immunotherapies with the potential to avoid wasting lives and revolutionise most cancers therapy.”

The analysis highlights the rising potential of extracellular vesicles as secure and versatile carriers for nucleic acid-based therapies. Past pancreatic most cancers, the platform could also be tailored to different KRAS-driven malignancies and mixed with current immunotherapies to enhance therapy outcomes.

Reference: Phung CD, Tran TTT, Yeo BZJ, et al. Mixture of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment in direction of efficient therapy of KRAS-dependent cancers. Theranostics. 2025;15(14):6818-6838. doi: 10.7150/thno.105519

This text has been republished from the next materials. Be aware: materials could have been edited for size and content material. For additional info, please contact the cited supply. Our press launch publishing coverage may be accessed here.